Results 151 to 160 of about 172,424 (309)
Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler +4 more
wiley +1 more source
T S Mohamed Saleem1, K Bharani1, K Gauthaman21Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet-516126, Kadapa Dist, Andhra Pradesh, India; 2Department of Drug Technology, Higher Institute of Medical Technology, Derna, LibyaAbstract:
T S Mohamed Saleem +2 more
doaj
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang +8 more
wiley +1 more source
Regulation of the renin–angiotensin system in coronary atherosclerosis: A review of the literature
Ramadan A Hammoud, Christopher S Vaccari, Sameer H Nagamia, Bobby V KhanEmory University School of Medicine, Division of Cardiology, Grady Memorial Hospital Vascular Research Laboratory, Atlanta, Georgia, USAAbstract: Activation of the renin&ndash ...
Ramadan A Hammoud +3 more
doaj
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho +4 more
wiley +1 more source
Angiotensin I‐converting enzyme (ACE) contains two catalytic domains (nACE and cACE) and is a key therapeutic target for hypertension and cardiovascular disease. Current ACE inhibitors (ACEi) nonselectively inhibit both domains, causing adverse effects. Selective inhibition requires an understanding of domain‐specific binding.
Kyle S. Gregory +3 more
wiley +1 more source
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? [PDF]
McInnes, G.T.
core +2 more sources
Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich +7 more
wiley +1 more source

